Full Version | Search

The Irish Medicines Board - www.imb.ie

Your Selection

[x] Product: Human medicines
[x] Document Type: Direct Healthcare Professional Communication
[x] Remove All Filters

By Audience / Stakeholder Group

By Service

Controlled Drugs (2)

Volibris (ambrisentan) - Important Safety Information from GlaxoSmithKline as approved by the Irish Medicines Board

24 July 2012

Tags: Human medicines Healthcare professionals Direct Healthcare Professional Communication

Important Safety Information from GlaxoSmithKline, Volibirs (ambrisentan) must not be used in patients with Idiopathic Pulmonary Fibrosis (IPF).

Important safety information - Volibiris (ambrisentan)

« View Publications List

Provide Feedback

RSS Feeds

IMB Publications RSS Feed

Date Printed: 18 May 2013

© Irish Medicines Board 2013 | Developed by Engine Solutions www.engine.ie

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971